John W. Crowley Sells 6,755 Shares of Lantheus Holdings, Inc. (LNTH) Stock
Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO John W. Crowley sold 6,755 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The stock was sold at an average price of $18.41, for a total transaction of $124,359.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Lantheus Holdings, Inc. (NASDAQ LNTH) opened at 17.55 on Thursday. The company has a market capitalization of $655.49 million, a price-to-earnings ratio of 23.98 and a beta of 0.91. The company’s 50-day moving average is $17.65 and its 200-day moving average is $17.65. Lantheus Holdings, Inc. has a 12-month low of $7.65 and a 12-month high of $20.45.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 EPS for the quarter, topping the consensus estimate of $0.24 by $0.18. The company had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. Lantheus Holdings’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 earnings per share. Analysts predict that Lantheus Holdings, Inc. will post $1.12 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its position in shares of Lantheus Holdings by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after purchasing an additional 4,084 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Lantheus Holdings by 24.8% during the second quarter. First Trust Advisors LP now owns 23,468 shares of the medical equipment provider’s stock worth $414,000 after purchasing an additional 4,669 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Lantheus Holdings by 28.9% during the first quarter. Parametric Portfolio Associates LLC now owns 22,530 shares of the medical equipment provider’s stock worth $282,000 after purchasing an additional 5,058 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Lantheus Holdings during the second quarter worth $102,000. Finally, Municipal Employees Retirement System of Michigan bought a new stake in shares of Lantheus Holdings during the second quarter worth $107,000. 84.34% of the stock is owned by institutional investors.
A number of brokerages have recently weighed in on LNTH. Jefferies Group LLC restated a “buy” rating and issued a $22.00 price objective (up from $18.00) on shares of Lantheus Holdings in a report on Wednesday, August 2nd. Zacks Investment Research lowered shares of Lantheus Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, September 20th. Cantor Fitzgerald began coverage on shares of Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 price objective for the company. Credit Suisse Group boosted their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. Finally, BidaskClub lowered shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.60.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.